Clinical Trial Update: Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the effects of 0.1% Nepafenac on vitreous inflammatory biomarkers in rhegmatogenous retinal detachment and proliferative vitre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Nepafenac (nepafenac)

Snippet

Sponsor: Indonesia University | Conditions: Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 4 | Status: COMPLETED